On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

In four treatment arms, three different doses of asunercept plus standard of care versus standard of care alone were evaluated in a total of 400 patients. Apogenix received regulatory approval for the ASUNCTIS trial in both Spain andRussia and planned to enroll patients in multiple study centers in Madrid and Saint Petersburg, among others.